SlideShare una empresa de Scribd logo
1 de 20
Pediatrics pharmacology
Dr.Azad Abduljabar Haleem
azad82d@gmail.com
•
•
•
•
•
•
•
•

Childhood: 0 – 18 years
Neonate: 28 days
Infant: 1st year
Toddlers: 2-3 years
Preschoool:3-5 years
School: 5-18 years
Early adolescent:10-14 years
Late adolescent: 14-18 years
• Pharmacokinetics is what the body does to a
drug,
• pharmacodynamics is what the drug does to
the body.
Absorption
• Neonates; have -reduced gastric acid secretion,
therefore the extent of drug absorption is altered
and less predictable.
• At birth, drugs with an acidic pH will have
decreased absorption.
• Twenty-four hours after birth, acid is released
into the stomach therefore increasing the
absorption of acidic drugs.
• Normal adult gastric acid secretions are achieved
by about 3 years of age.
• Gastric motility is decreased during infancy,
thus increasing the absorption of drugs that
are absorbed in the stomach.
• However, drugs absorbed from the intestine
will have a decreased or possibly delayed
absorption.
Distribution
• The concentration of a drug at various sites of
action depends on the drug's characteristics
and those of the tissue.
• Most drugs are water-soluble and will
naturally go to organs such as the kidneys,
liver, heart and gastrointestinal tract.
• At birth, the total body water and extracellular
fluid volume are much increased, and thus
larger doses of water-soluble drugs are
required on a mg/kg basis to achieve
equivalent concentrations to those seen in
older children and adults.
• This has to be balanced against the diminished
hepatic and renal function when considering
dosing.
• Distribution is also affected by a decreased
protein-binding capacity in newborns, and
particularly in pre-term newborns,
• therefore leading to increased levels of the
active free drug for highly protein-bound
drugs.
• For example, phenytoin is highly protein-bound
but because there is less protein binding in
neonates (lower plasma protein levels and lower
binding capacity) there is more free phenytoin
than in older children and adults.
• Thus the therapeutic range for phenytoin in
neonates is lower than in the rest of the general
population as it is the free phenytoin that has the
therapeutic action and can cause toxicity.
• • Therapeutic range for neonates = 6-15 mg/kg
• • Therapeutic range for children and adults = 1020 mg/kg
Blood-brain barrier:
• The blood-brain barrier in the newborn is
functionally incomplete and hence there is an
increased penetration of some drugs into the
brain.
• Transfer across the barrier is determined by:
• • Lipid solubility
• • Degree of ionization
• Drugs that are predominantly un-ionized are
more lipid-soluble and achieve higher
concentrations in the cerebrospinal fluid.
• It is as a result of this increased uptake that
neonates are generally more sensitive to the
respiratory depressant effects of opiates than
infants and older children.
• Some drugs will displace bilirubin from
albumin (for example: sulphonamides),
• so increasing the risk of kernicterus
(encephalopathy due to increased bilirubin in
the central nervous system - in at-risk
neonates).
Hepatic metabolism
• Hepatic metabolism is generally slower at birth
compared with adults.
• However, it increases rapidly during the first few
weeks of life, so that in late infancy hepatic
metabolism may be more effective than in adults.
• The age at which the enzyme processes approach
adult values varies with drug and the metabolic
pathway.
• For drugs such as diazepam, which are
extensively metabolized by the liver, the decrease
in half-life with age demonstrates this process.
• The hepatic metabolism process occurs either
by sulphation, methylation, oxidation,
hydroxylation or glucuronidation.
• Most hepatically metabolized drugs will
undergo one or two of these processes.
• Processes involving sulphation and
methylation are not greatly impaired at birth,
• whereas those involving oxidation and
glucuronidation are.
• It might be assumed that neonates would be
at an increased risk of paracetamol toxicity;
however, neonates use the sulphation
pathway instead of glucuronidation and are
able to deal with paracetamol .
• Hydroxylation of drugs is deficient in
newborns, particularly in pre-term babies, and
this is the process that accounts for the huge
variation in diazepam .
• Grey-baby syndrome is a rare, but potentially
fatal, toxic effect of chloramphenicol in
neonates.
• It is the result of the inability of the liver to
glucuronidate the drug effectively in the first
couple of weeks of life if correct doses are not
given.
Renal excretion
• Drug excretion by the kidneys is mainly
dependent on glomerular filtration and active
renal tubule secretion.
• Pre-term infants have approximately 15% (or less)
of the renal capacity of an adult,
• term babies have about 30% at birth,
• but this matures rapidly to about 50% of the
adult capacity by the time they are 4-5 weeks old.
• At 9-12 months of age, the infant's renal capacity
is equal to that of an adult.
Thanks
Pediatrics prescribing
• Legal responsibility lies with the doctor who
signs the prescriptions??
pediatrics pharmacology

Más contenido relacionado

La actualidad más candente

Drugs used in special age groups like children, elderly and preganancy
Drugs used in special age groups like children, elderly and preganancyDrugs used in special age groups like children, elderly and preganancy
Drugs used in special age groups like children, elderly and preganancy
Roopali Somani
 
Drug therapy-Neonates and pediatrics
Drug therapy-Neonates and pediatricsDrug therapy-Neonates and pediatrics
Drug therapy-Neonates and pediatrics
Tsegaye Melaku
 

La actualidad más candente (20)

Drug Promotional Literature
Drug Promotional LiteratureDrug Promotional Literature
Drug Promotional Literature
 
Drugs used in pediatrics
Drugs used in pediatricsDrugs used in pediatrics
Drugs used in pediatrics
 
Pediatric Medication
Pediatric MedicationPediatric Medication
Pediatric Medication
 
Drug use in paediatric & geriatric patients
Drug use in paediatric & geriatric patientsDrug use in paediatric & geriatric patients
Drug use in paediatric & geriatric patients
 
Teratogenecity
TeratogenecityTeratogenecity
Teratogenecity
 
Drugs used in special age groups like children, elderly and preganancy
Drugs used in special age groups like children, elderly and preganancyDrugs used in special age groups like children, elderly and preganancy
Drugs used in special age groups like children, elderly and preganancy
 
Drugs used in pregnancy
Drugs used in pregnancyDrugs used in pregnancy
Drugs used in pregnancy
 
Oral hypoglycemics
Oral hypoglycemicsOral hypoglycemics
Oral hypoglycemics
 
Macrolide antibiotics
Macrolide antibioticsMacrolide antibiotics
Macrolide antibiotics
 
Anti Tubercular Drugs - Mechanism of Action and Adverse effects
Anti Tubercular Drugs - Mechanism of Action and Adverse effects Anti Tubercular Drugs - Mechanism of Action and Adverse effects
Anti Tubercular Drugs - Mechanism of Action and Adverse effects
 
Effects of Liver disease on Pharmacokinetics
Effects of Liver disease on Pharmacokinetics Effects of Liver disease on Pharmacokinetics
Effects of Liver disease on Pharmacokinetics
 
Antidiabetic drugs
Antidiabetic drugsAntidiabetic drugs
Antidiabetic drugs
 
Pediatric pharmacotherapy
Pediatric pharmacotherapyPediatric pharmacotherapy
Pediatric pharmacotherapy
 
Drug interactions
Drug interactionsDrug interactions
Drug interactions
 
Antiepileptics
Antiepileptics Antiepileptics
Antiepileptics
 
digoxin Therapeutic drug monitoring
digoxin Therapeutic drug monitoring digoxin Therapeutic drug monitoring
digoxin Therapeutic drug monitoring
 
Drug therapy-Neonates and pediatrics
Drug therapy-Neonates and pediatricsDrug therapy-Neonates and pediatrics
Drug therapy-Neonates and pediatrics
 
Pharmacokinetics of drug interaction
Pharmacokinetics of drug interactionPharmacokinetics of drug interaction
Pharmacokinetics of drug interaction
 
Dosing of drugs in liver failure
Dosing of drugs in liver failureDosing of drugs in liver failure
Dosing of drugs in liver failure
 
Dosing in obese patient
Dosing in obese patientDosing in obese patient
Dosing in obese patient
 

Destacado

Clinical pharmacology in special populations 2014
Clinical pharmacology in special populations 2014Clinical pharmacology in special populations 2014
Clinical pharmacology in special populations 2014
vanessawhitehawk
 
Drug receptors in pharmacology
Drug receptors in pharmacologyDrug receptors in pharmacology
Drug receptors in pharmacology
Bindu Pulugurtha
 

Destacado (9)

Pharmacology basic concept
Pharmacology basic conceptPharmacology basic concept
Pharmacology basic concept
 
Pediatric pharmacology by dr.azad al.kurdi
Pediatric pharmacology by dr.azad al.kurdiPediatric pharmacology by dr.azad al.kurdi
Pediatric pharmacology by dr.azad al.kurdi
 
Clinical pharmacology in special populations 2014
Clinical pharmacology in special populations 2014Clinical pharmacology in special populations 2014
Clinical pharmacology in special populations 2014
 
Congenital Cyanotic Heart Disease & TOF - Dr. D. Gunasekaran
Congenital Cyanotic Heart Disease & TOF - Dr. D. GunasekaranCongenital Cyanotic Heart Disease & TOF - Dr. D. Gunasekaran
Congenital Cyanotic Heart Disease & TOF - Dr. D. Gunasekaran
 
Acyanotic Congenital Heart Disease - ASD (Dr. Gunasekaran)
Acyanotic Congenital Heart Disease - ASD (Dr. Gunasekaran)Acyanotic Congenital Heart Disease - ASD (Dr. Gunasekaran)
Acyanotic Congenital Heart Disease - ASD (Dr. Gunasekaran)
 
Vital signs pediatrics
Vital signs pediatricsVital signs pediatrics
Vital signs pediatrics
 
Factors modifying drug action
Factors modifying drug actionFactors modifying drug action
Factors modifying drug action
 
Patent ductus arteriosus
Patent ductus arteriosusPatent ductus arteriosus
Patent ductus arteriosus
 
Drug receptors in pharmacology
Drug receptors in pharmacologyDrug receptors in pharmacology
Drug receptors in pharmacology
 

Similar a pediatrics pharmacology

Pharmacology for pediatric anaesthesia [autosaved]
Pharmacology for pediatric anaesthesia [autosaved]Pharmacology for pediatric anaesthesia [autosaved]
Pharmacology for pediatric anaesthesia [autosaved]
DeepakGupta825
 

Similar a pediatrics pharmacology (20)

Pediatric Pharmacology:Pharmacokinetics and pharmacodynamics .pptx
Pediatric  Pharmacology:Pharmacokinetics and pharmacodynamics  .pptxPediatric  Pharmacology:Pharmacokinetics and pharmacodynamics  .pptx
Pediatric Pharmacology:Pharmacokinetics and pharmacodynamics .pptx
 
Paediatric Pharmacology Part-2.pptx
Paediatric Pharmacology Part-2.pptxPaediatric Pharmacology Part-2.pptx
Paediatric Pharmacology Part-2.pptx
 
POSOLOGY.pptx
POSOLOGY.pptxPOSOLOGY.pptx
POSOLOGY.pptx
 
Pharmacology for pediatric anaesthesia [autosaved]
Pharmacology for pediatric anaesthesia [autosaved]Pharmacology for pediatric anaesthesia [autosaved]
Pharmacology for pediatric anaesthesia [autosaved]
 
Paediatrics
PaediatricsPaediatrics
Paediatrics
 
Clinical pharmacy age factors : Features of the Rational use of Medicines
Clinical pharmacy age factors : Features of the Rational use of MedicinesClinical pharmacy age factors : Features of the Rational use of Medicines
Clinical pharmacy age factors : Features of the Rational use of Medicines
 
P'kinetics &; drug therapy
P'kinetics  &; drug therapyP'kinetics  &; drug therapy
P'kinetics &; drug therapy
 
Geriatric & Pediatrics Pharmacology
Geriatric & Pediatrics Pharmacology  Geriatric & Pediatrics Pharmacology
Geriatric & Pediatrics Pharmacology
 
prescribing in paediatrics.pptx
prescribing in paediatrics.pptxprescribing in paediatrics.pptx
prescribing in paediatrics.pptx
 
Pharmacologic considerations in pediatric dentistry
Pharmacologic considerations in pediatric dentistryPharmacologic considerations in pediatric dentistry
Pharmacologic considerations in pediatric dentistry
 
Pharmacodynamics in pregnancy and placenta.pptx
Pharmacodynamics in pregnancy and placenta.pptxPharmacodynamics in pregnancy and placenta.pptx
Pharmacodynamics in pregnancy and placenta.pptx
 
Pediatrics, Geriatrics, Pregnancy, Lactation
Pediatrics, Geriatrics, Pregnancy, LactationPediatrics, Geriatrics, Pregnancy, Lactation
Pediatrics, Geriatrics, Pregnancy, Lactation
 
GENERAL PRESCRIBING GUIDELINES FOR PAEDIATRIC PATIENTS.pptx
GENERAL PRESCRIBING GUIDELINES FOR PAEDIATRIC PATIENTS.pptxGENERAL PRESCRIBING GUIDELINES FOR PAEDIATRIC PATIENTS.pptx
GENERAL PRESCRIBING GUIDELINES FOR PAEDIATRIC PATIENTS.pptx
 
Analgesic in Pedo-Part 1.pptx
Analgesic in Pedo-Part 1.pptxAnalgesic in Pedo-Part 1.pptx
Analgesic in Pedo-Part 1.pptx
 
Pediatrics
PediatricsPediatrics
Pediatrics
 
Paediatric (pediatrics) medication-drugs therapy in pediatrics
Paediatric (pediatrics) medication-drugs therapy in pediatricsPaediatric (pediatrics) medication-drugs therapy in pediatrics
Paediatric (pediatrics) medication-drugs therapy in pediatrics
 
Drug distribution in pediatrics
Drug distribution in pediatricsDrug distribution in pediatrics
Drug distribution in pediatrics
 
Factors modifying drug actions & effects
Factors modifying drug actions & effectsFactors modifying drug actions & effects
Factors modifying drug actions & effects
 
Posology.pptx
Posology.pptxPosology.pptx
Posology.pptx
 
TDM POINTERS [GERIATIC & PAEDIATRIC PATIENTS].pdf
TDM POINTERS [GERIATIC & PAEDIATRIC PATIENTS].pdfTDM POINTERS [GERIATIC & PAEDIATRIC PATIENTS].pdf
TDM POINTERS [GERIATIC & PAEDIATRIC PATIENTS].pdf
 

Más de Azad Haleem

Más de Azad Haleem (20)

Precocious Puberty in Girl approach and Management
Precocious Puberty in Girl approach and ManagementPrecocious Puberty in Girl approach and Management
Precocious Puberty in Girl approach and Management
 
Diagnosis & Management of Hypoglycemia in Children
Diagnosis & Management of Hypoglycemia in ChildrenDiagnosis & Management of Hypoglycemia in Children
Diagnosis & Management of Hypoglycemia in Children
 
Neonatal Hypoglycemia approach and Management .pptx
Neonatal Hypoglycemia approach and Management .pptxNeonatal Hypoglycemia approach and Management .pptx
Neonatal Hypoglycemia approach and Management .pptx
 
Preterm infants Nutrition .pptx
Preterm infants Nutrition .pptxPreterm infants Nutrition .pptx
Preterm infants Nutrition .pptx
 
Preterm : ABCDE; approach to nutritional assessment in preterm infants.pptx
Preterm : ABCDE; approach to nutritional assessment in preterm infants.pptxPreterm : ABCDE; approach to nutritional assessment in preterm infants.pptx
Preterm : ABCDE; approach to nutritional assessment in preterm infants.pptx
 
Breastfeeding VS formula feeding .pptx
 Breastfeeding VS formula feeding .pptx Breastfeeding VS formula feeding .pptx
Breastfeeding VS formula feeding .pptx
 
Role of Supplements in Growth Failure in Children .pptx
Role of Supplements in Growth Failure in Children .pptxRole of Supplements in Growth Failure in Children .pptx
Role of Supplements in Growth Failure in Children .pptx
 
Degludec Insulin therapy in children
Degludec Insulin therapy in childrenDegludec Insulin therapy in children
Degludec Insulin therapy in children
 
Viral hemorrhagic fevers.pptx
Viral hemorrhagic fevers.pptxViral hemorrhagic fevers.pptx
Viral hemorrhagic fevers.pptx
 
Micronutrient deficiencies in children .pptx
 Micronutrient deficiencies in children  .pptx Micronutrient deficiencies in children  .pptx
Micronutrient deficiencies in children .pptx
 
Insulin therapy in children.pptx
Insulin therapy in children.pptxInsulin therapy in children.pptx
Insulin therapy in children.pptx
 
Diagnostic test for testicular and ovarian disorders in children 2.pptx
Diagnostic test for testicular and ovarian disorders in children 2.pptxDiagnostic test for testicular and ovarian disorders in children 2.pptx
Diagnostic test for testicular and ovarian disorders in children 2.pptx
 
Diagnostic test for Adrenal disorders in children 2.pptx
Diagnostic test for Adrenal disorders in children 2.pptxDiagnostic test for Adrenal disorders in children 2.pptx
Diagnostic test for Adrenal disorders in children 2.pptx
 
Diagnostic test for Thyriod disorders in children.pptx
Diagnostic test for Thyriod disorders in children.pptxDiagnostic test for Thyriod disorders in children.pptx
Diagnostic test for Thyriod disorders in children.pptx
 
Achondroplasia in children.pptx
Achondroplasia in children.pptxAchondroplasia in children.pptx
Achondroplasia in children.pptx
 
Respiratory Syncytial Virus in children
Respiratory Syncytial Virus in childrenRespiratory Syncytial Virus in children
Respiratory Syncytial Virus in children
 
Growth failure in Children.pptx
Growth failure in Children.pptxGrowth failure in Children.pptx
Growth failure in Children.pptx
 
Adenoid Enlargement in children.pptx
Adenoid Enlargement in children.pptxAdenoid Enlargement in children.pptx
Adenoid Enlargement in children.pptx
 
Postbiotics in children
 Postbiotics in children Postbiotics in children
Postbiotics in children
 
Bronchial Asthma in children .pptx
Bronchial Asthma in children .pptxBronchial Asthma in children .pptx
Bronchial Asthma in children .pptx
 

Último

The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
heathfieldcps1
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
heathfieldcps1
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
QucHHunhnh
 
Seal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxSeal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptx
negromaestrong
 

Último (20)

Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
Sociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning ExhibitSociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning Exhibit
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
PROCESS RECORDING FORMAT.docx
PROCESS      RECORDING        FORMAT.docxPROCESS      RECORDING        FORMAT.docx
PROCESS RECORDING FORMAT.docx
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptx
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
 
Class 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdfClass 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdf
 
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
 
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-IIFood Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdf
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
 
Energy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural Resources
Energy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural ResourcesEnergy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural Resources
Energy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural Resources
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and Mode
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
 
Seal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxSeal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptx
 

pediatrics pharmacology

  • 2. • • • • • • • • Childhood: 0 – 18 years Neonate: 28 days Infant: 1st year Toddlers: 2-3 years Preschoool:3-5 years School: 5-18 years Early adolescent:10-14 years Late adolescent: 14-18 years
  • 3. • Pharmacokinetics is what the body does to a drug, • pharmacodynamics is what the drug does to the body.
  • 4. Absorption • Neonates; have -reduced gastric acid secretion, therefore the extent of drug absorption is altered and less predictable. • At birth, drugs with an acidic pH will have decreased absorption. • Twenty-four hours after birth, acid is released into the stomach therefore increasing the absorption of acidic drugs. • Normal adult gastric acid secretions are achieved by about 3 years of age.
  • 5. • Gastric motility is decreased during infancy, thus increasing the absorption of drugs that are absorbed in the stomach. • However, drugs absorbed from the intestine will have a decreased or possibly delayed absorption.
  • 6. Distribution • The concentration of a drug at various sites of action depends on the drug's characteristics and those of the tissue. • Most drugs are water-soluble and will naturally go to organs such as the kidneys, liver, heart and gastrointestinal tract.
  • 7. • At birth, the total body water and extracellular fluid volume are much increased, and thus larger doses of water-soluble drugs are required on a mg/kg basis to achieve equivalent concentrations to those seen in older children and adults. • This has to be balanced against the diminished hepatic and renal function when considering dosing.
  • 8. • Distribution is also affected by a decreased protein-binding capacity in newborns, and particularly in pre-term newborns, • therefore leading to increased levels of the active free drug for highly protein-bound drugs.
  • 9. • For example, phenytoin is highly protein-bound but because there is less protein binding in neonates (lower plasma protein levels and lower binding capacity) there is more free phenytoin than in older children and adults. • Thus the therapeutic range for phenytoin in neonates is lower than in the rest of the general population as it is the free phenytoin that has the therapeutic action and can cause toxicity. • • Therapeutic range for neonates = 6-15 mg/kg • • Therapeutic range for children and adults = 1020 mg/kg
  • 10. Blood-brain barrier: • The blood-brain barrier in the newborn is functionally incomplete and hence there is an increased penetration of some drugs into the brain. • Transfer across the barrier is determined by: • • Lipid solubility • • Degree of ionization
  • 11. • Drugs that are predominantly un-ionized are more lipid-soluble and achieve higher concentrations in the cerebrospinal fluid. • It is as a result of this increased uptake that neonates are generally more sensitive to the respiratory depressant effects of opiates than infants and older children.
  • 12. • Some drugs will displace bilirubin from albumin (for example: sulphonamides), • so increasing the risk of kernicterus (encephalopathy due to increased bilirubin in the central nervous system - in at-risk neonates).
  • 13. Hepatic metabolism • Hepatic metabolism is generally slower at birth compared with adults. • However, it increases rapidly during the first few weeks of life, so that in late infancy hepatic metabolism may be more effective than in adults. • The age at which the enzyme processes approach adult values varies with drug and the metabolic pathway. • For drugs such as diazepam, which are extensively metabolized by the liver, the decrease in half-life with age demonstrates this process.
  • 14. • The hepatic metabolism process occurs either by sulphation, methylation, oxidation, hydroxylation or glucuronidation. • Most hepatically metabolized drugs will undergo one or two of these processes. • Processes involving sulphation and methylation are not greatly impaired at birth, • whereas those involving oxidation and glucuronidation are.
  • 15. • It might be assumed that neonates would be at an increased risk of paracetamol toxicity; however, neonates use the sulphation pathway instead of glucuronidation and are able to deal with paracetamol . • Hydroxylation of drugs is deficient in newborns, particularly in pre-term babies, and this is the process that accounts for the huge variation in diazepam .
  • 16. • Grey-baby syndrome is a rare, but potentially fatal, toxic effect of chloramphenicol in neonates. • It is the result of the inability of the liver to glucuronidate the drug effectively in the first couple of weeks of life if correct doses are not given.
  • 17. Renal excretion • Drug excretion by the kidneys is mainly dependent on glomerular filtration and active renal tubule secretion. • Pre-term infants have approximately 15% (or less) of the renal capacity of an adult, • term babies have about 30% at birth, • but this matures rapidly to about 50% of the adult capacity by the time they are 4-5 weeks old. • At 9-12 months of age, the infant's renal capacity is equal to that of an adult.
  • 19. Pediatrics prescribing • Legal responsibility lies with the doctor who signs the prescriptions??